FDA Rejects Sunscreen TEAs, Plans Public Hearing On Ingredient Review
This article was originally published in The Tan Sheet
Executive Summary
Answering time-and-extent applications, FDA finds data insufficient to affirm the safety of amiloxate and diethylhexyl butamido triazone as sunscreen ingredients. The agency asks for further information in support of the ingredients’ safety and plans a public meeting on its evaluation of OTC sunscreen ingredients.
You may also be interested in...
Reps Prep Sunscreen Filter Legislation; FDA Frustrated By Backlog
Without swift FDA action on eight sunscreen filters pending review, legislators intend to introduce a bill to alter the agency’s sunscreen approval process. House members questioned FDA Center for Drug Evaluation and Research Director Janet Woodcock on the status of the applications, some of which have been under agency review for more than 10 years.
House Pushes FDA To Expedite Sunscreen Ingredient Reviews
Reps. Dingell and Whitfield ask for FDA’s assistance on legislation they are writing to expedite the agency’s review of additional sunscreen ingredients. CDER Director Woodcock pledges FDA help, but explains the agency’s OTC ingredient reviews are “backlogged.”
FDA Strengthens Sunscreen Testing And Label Requirements
As early as June 2012, sunscreens that fail “broad spectrum” tests or have an SPF less than 15 must warn that they have not been shown to prevent cancer or early skin aging, according to an FDA final rule.